Total Payments
$1,134
2024 Payments
$262.39
Companies
10
Transactions
20
Medicare Patients
669
Medicare Billing
$135,579
Payment Breakdown by Category
Food & Beverage$1,134 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,134 | 20 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $214.01 | 2 | $0 (2023) |
| Galvanize Therapeutics, Inc | $152.63 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $143.85 | 2 | $0 (2021) |
| EISAI INC. | $142.11 | 2 | $0 (2022) |
| Astellas Pharma US Inc | $124.03 | 1 | $0 (2023) |
| Celgene Corporation | $106.05 | 5 | $0 (2020) |
| Intera Oncology, Inc | $90.12 | 1 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $71.31 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $70.19 | 4 | $0 (2021) |
| ARRAY BIOPHARMA INC | $19.64 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $262.39 | 3 | Galvanize Therapeutics, Inc ($152.63) |
| 2023 | $409.35 | 4 | Medtronic, Inc. ($214.01) |
| 2022 | $117.79 | 1 | EISAI INC. ($117.79) |
| 2021 | $159.23 | 3 | AstraZeneca Pharmaceuticals LP ($143.85) |
| 2020 | $18.17 | 1 | Celgene Corporation ($18.17) |
| 2019 | $80.71 | 4 | Merck Sharp & Dohme Corporation ($37.36) |
| 2018 | $68.85 | 3 | Celgene Corporation ($68.85) |
| 2017 | $17.45 | 1 | Merck Sharp & Dohme Corporation ($17.45) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Galvanize Therapeutics, Inc | ALIYA SYSTEM (Device) | Food and Beverage | In-kind items and services | $152.63 | General |
| Category: PULSED ELECTRIC FIELD | ||||||
| 04/23/2024 | Intera Oncology, Inc | INTERA (Device) | Food and Beverage | In-kind items and services | $90.12 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2023 | Medtronic, Inc. | LIGASURE (Device) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Vessel Sealing | ||||||
| 11/22/2023 | Medtronic, Inc. | LIGASURE (Device) | Food and Beverage | In-kind items and services | $195.26 | General |
| Category: Vessel Sealing | ||||||
| 08/03/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug), Stivarga | Food and Beverage | In-kind items and services | $71.31 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $124.03 | General |
| 06/16/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $117.79 | General |
| Category: Oncology | ||||||
| 10/23/2021 | AstraZeneca Pharmaceuticals LP | CRESTOR (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 05/15/2020 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $18.17 | General |
| 09/06/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Oncology | ||||||
| 08/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.32 | General |
| Category: Oncology | ||||||
| 03/01/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Oncology | ||||||
| 11/02/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Oncology | ||||||
| 07/20/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Oncology | ||||||
| 11/10/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $17.45 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 147 | 329 | $138,770 | $37,010 |
| 2022 | 4 | 130 | 271 | $99,350 | $26,935 |
| 2021 | 6 | 187 | 397 | $153,940 | $42,115 |
| 2020 | 6 | 205 | 395 | $131,980 | $29,519 |
Total Patients
669
Total Services
1,392
Medicare Billing
$135,579
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 41 | 169 | $74,360 | $21,588 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 80 | $24,800 | $6,595 | 26.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 26 | $20,800 | $4,189 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $8,710 | $2,159 | 24.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 19 | $5,700 | $1,335 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 22 | $4,400 | $1,144 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 134 | $41,540 | $11,419 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 34 | 91 | $40,040 | $11,071 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $12,060 | $2,956 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 28 | $5,710 | $1,489 | 26.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 47 | 150 | $66,000 | $19,420 | 29.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 68 | 143 | $44,330 | $12,385 | 27.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $15,410 | $3,862 | 25.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 48 | $14,400 | $3,206 | 22.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $9,600 | $2,070 | 21.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 21 | $4,200 | $1,172 | 27.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 65 | 180 | $55,800 | $12,327 | 22.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $18,090 | $4,291 | 23.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 46 | 84 | $16,800 | $3,861 | 23.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 21 | 32 | $14,080 | $3,155 | 22.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 40 | $12,000 | $2,681 | 22.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $9,700 | $2,289 | 23.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 19 | $5,510 | $916.73 | 16.6% |
About Celina Ang
Celina Ang is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2011. The National Provider Identifier (NPI) number assigned to this provider is 1134423940.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Celina Ang has received a total of $1,134 in payments from pharmaceutical and medical device companies, with $262.39 received in 2024. These payments were reported across 20 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,134).
As a Medicare-enrolled provider, Ang has provided services to 669 Medicare beneficiaries, totaling 1,392 services with total Medicare billing of $135,579. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/08/2011
- Last Updated 03/11/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1134423940
Products in Payments
- LIGASURE (Device) $214.01
- ALIYA SYSTEM (Device) $152.63
- Lenvima (Drug) $142.11
- INTERA (Device) $90.12
- Abraxane (Drug) $87.88
- Vitrakvi (Drug) $71.31
- KEYTRUDA (Biological) $52.74
- LORBRENA (Drug) $19.64
- CRESTOR (Drug) $18.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555